Evidence-based diagnosis of Lyme disease

Lyme disease diagnosis relies heavily on serological testing, yet variability in assay performance creates uncertainty in results. Prior research has shown that enzyme immunoassays (EIAs) are commonly used for initial screening, but differences in sensitivity and specificity across commercial assays remain poorly resolved. This gap motivated the need for a direct comparative analysis of multiple EIAs to determine which offers the best balance of diagnostic accuracy and cost. No prior work had resolved how these assays perform when tested against a standardized panel of sera. The challenge lies in selecting a screening assay that minimizes false positives and false negatives while maintaining economic feasibility. This uncertainty drives the need for evidence-based evaluation of commercial and in-house EIAs. The study addresses this by comparing five assays using a well-characterized serum panel. The findings aim to guide diagnostic protocols in specialist laboratories.

This study aimed to evaluate and compare the diagnostic performance of four commercial enzyme immunoassays (EIAs) and one in-house EIA for Lyme disease. The goal was to identify which assay offers the best combination of sensitivity and specificity when used as a screening test followed by Western blot confirmation. The researchers proposed that an optimal screening assay should minimize the number of tests needed per positive diagnosis while maintaining diagnostic accuracy. The motivation for this work stems from the lack of consensus on which EIA is most suitable for European diagnostic settings. The study focused on cost-effectiveness and diagnostic reliability in specialist laboratories. The researchers proposed that an evidence-based comparison would help resolve current diagnostic uncertainties. The study tested this hypothesis using a standardized panel of sera with known Western blot results. The findings aim to inform diagnostic protocols and improve patient outcomes.

The study compared five enzyme immunoassays (EIAs) for detecting antibodies to Borrelia burgdorferi in a panel of 176 sera. The assays included four commercial EIAs and one in-house EIA developed using Borrelia burgdorferi cultured in BSK-H medium. A serum diluent containing Escherichia coli antigen was used to reduce non-specific background in the in-house assay. The performance of each EIA was evaluated based on sensitivity, specificity, and the number of tests required to diagnose a positive case. The researchers calculated the cost per positive diagnosis for each assay. The sera used in the study were characterized by Western blot to ensure accurate classification. The comparison focused on how well each EIA performed in terms of diagnostic accuracy and economic efficiency. The results were analyzed to determine which assay best balances sensitivity and specificity.

The Cambridge Biotech and Sigma assays showed the highest sensitivity but lower specificity, while the Serion and ICN assays had the highest specificity but lower sensitivity. The in-house assay demonstrated average sensitivity and specificity, with a number of tests needed to diagnose of 2.32. This was slightly higher than the 1.92 for Serion, 2.17 for ICN, 2.5 for Sigma, and 2.7 for Cambridge Biotech. The in-house assay had the lowest cost per positive diagnosis compared to the commercial assays. The study found that a good balance of sensitivity and specificity is essential for an effective screening protocol followed by Western blot confirmation. The in-house assay was identified as the most cost-effective option for specialist laboratories. The researchers propose that this assay is likely the best choice for use in European diagnostic settings. The results suggest that the in-house assay may be more suitable for routine diagnostic use.

The authors propose that the in-house enzyme immunoassay (EIA) offers the best balance of diagnostic accuracy and cost-effectiveness for screening Lyme disease in specialist laboratories. The study suggests that the in-house assay is more efficient than the commercial EIAs tested. The researchers propose that the in-house assay may be the most suitable option for use in European diagnostic settings. The findings indicate that the in-house assay requires fewer tests per positive diagnosis compared to other assays. The study suggests that the in-house assay is more cost-effective than the commercial EIAs. The authors propose that the in-house assay may be more reliable for use in a two-step diagnostic protocol involving Western blot confirmation. The study suggests that the in-house assay provides a good compromise between sensitivity and specificity. The authors conclude that the in-house assay is likely the best option for specialist laboratories in Europe.